IP Library Granted Patent US 9,133,500
Granted Patent B2
US 9,133,500 · App. 13/379,680 · Granted Sep 15, 2015

Screening strategies for the identification of binders

Inventors: Christian Frisch (München, DE); Achim Knappik (Moorenweis, DE); Alex Y. Strongin (San Diego, CA); Sergey A. Shiryaev (San Diego, CA)
Assignee: MorphoSys A6
C12Q1/37C07K14/005C07K16/1081C07K16/40C07K2299/00C07K2317/21C07K2317/33C07K2317/515C07K2317/55C07K2317/565C07K2317/76C07K2317/92C12N2770/24122G01N2333/185G01N2333/95G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,133,500
App. No.
13/379,680
Granted
Sep 15, 2015
Kind
B2
Abstract

The present invention discloses novel screening strategies for the identification of binders that target the active site of enzymatic antigens. The present invention also discloses antigen-binding moieties which bind to the NS2B-NS3 Proteinase of West Nile Virus, in particular binders which bind to the active site, thereby inhibiting the enzymatic activity of the proteinase. The antigen-binding moieties of the present invention have numerous therapeutic and diagnostic applications.

Claims (13)

1. A method to identify antigen-binding moieties which bind to an epitope of a polypeptide, wherein said polypeptide comprises an enzymatic activity, said method comprising

(a) screening a library of antigen-binding moieties against a polypeptide comprising the epitope and having the enzymatic activity and isolating those members of said library that bind to said polypeptide,

(b) counter-screening the members of the library isolated in step (a) against a variant of the polypeptide, wherein said variant polypeptide comprises a mutated epitope and is devoid of enzymatic activity, and

(c) isolating those members that do not bind to said variant polypeptide, therein identifying those members that bind to the epitope of the polypeptide.

2. The method of claim 1 , wherein said variant polypeptide is an epitope mutant of the wild type polypeptide.

3. The method of claim 1 , wherein said epitope of the polypeptide only exists within one or more isoforms of the polypeptide.

4. The method of claim 1 , wherein said epitope of the polypeptide only exists in the monomeric, multimeric or heteromeric form of the polypeptide.

5. The method of claim 1 , wherein said polypeptide is a protease.

6. The method of claim 5 , wherein said protease is a viral protease.

7. The method according to claim 1 , further comprising

(d) testing if the antigen-binding moieties isolated in step (c) inhibit the enzymatic activity of the polypeptide.

8. The method of claim 6 , wherein said viral protease is the NS2B-NS3 protease of West Nile Virus.

9. The method of claim 1 , wherein the epitope is mutated by removal or the substitution of an amino acid.

Assignments (3)
CHANGE OF NAME Recorded May 1, 2025
From: MORPHOSYS AG
To: MORPHOSYS GMBH
Reel/Frame 071149/0626 →
EXCERPT OF COMMERCIAL REGISTER REFLECTING NEW ADDRESS Recorded Apr 28, 2017
From: MORPHOSYS AG
To: MORPHOSYS AG
Reel/Frame 042357/0552 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2012
From: FRISCH, CHRISTIAN, DR.; KNAPPIK, ACHIM, DR.; STRONGIN, ALEX; SHIRYAEV, SERGEY
To: MORPHOSYS AG
Reel/Frame 027824/0209 →
Continuity (3)
Provisional Application 61232561 · Aug 10, 2009
Provisional Application 61233504 · Aug 13, 2009
Related Publication 20120178909A1 · Jul 12, 2012